Published on 29/11/2025

DoE as a Bridge: Using Prior Knowledge for Faster Close

The pharmaceutical industry continually faces the need to implement efficient change control processes to ensure regulatory compliance while maintaining product quality. This necessitates a thorough understanding of the difference between verification and re-validation, as well as the role that Design of Experiments (DoE) can play as a bridge in change control processes. This article provides a comprehensive step-by-step guide for pharma professionals, clinical operations, and regulatory affairs specialists focused on risk-based change thresholds, bridging studies, sampling plan updates, CPV limit adjustments, and other crucial elements within the realm of change control.

Understanding Change Control Impact Assessment

Change control impact assessment is an essential component of the quality management system in the pharmaceutical industry. This process involves evaluating the potential impact of changes to any aspect of the production or quality assurance processes. A well-structured impact assessment serves to minimize risks associated with changes while ensuring compliance with regulatory expectations, such as those defined by FDA, EMA, and MHRA.

To effectively manage change control impact assessments, professionals should follow these key steps:

• Step 1: Define the Change – It is crucial to clearly outline what change is being proposed, whether it’s related to equipment, materials, processes, or facilities.
• Step 2: Identify Affected Components – Determine which components of the quality system might be affected by the change. This includes reviewing manufacturing processes, release specifications, and regulatory filings.
• Step 3: Assess Risk – Utilizing a risk-based approach, professionals must evaluate the potential impact of the change on product quality, safety, and efficacy. Consider factors such as CPV limits and historical data from past effectiveness checks.
• Step 4: Develop and Document Evidence Packs – Collect and document evidence to support the assessment. This might include validation data, prior knowledge, and results from bridging studies.
• Step 5: Review and Approve – Ensure that all relevant stakeholders, including quality assurance and regulatory affairs, review and approve the impact assessment before proceeding with the change.

By following these steps, companies can ensure that they have executed a thorough change control impact assessment, thereby reducing the likelihood of non-compliance and enhancing product quality.

Verification vs. Re-Validation: Key Considerations

Understanding the distinction between verification and re-validation is crucial in the context of change control. Verification refers to the confirmation that a process or system is functioning as intended, typically conducted at the time of implementation. In contrast, re-validation involves a more thorough review and testing of processes or systems that have undergone significant changes over time.

Considering the differences, here are critical considerations:

• When to Verify: Verify under conditions where low risks to product quality exist, such as minor adjustments to manufacturing processes.
• When to Re-Validate: Engage in re-validation when substantial changes impact critical processes, materials, or equipment. This may also be warranted under regulations set forth by ICH guidelines or as outlined in Annex 15 of the EU GMP guidelines.

Both verification and re-validation play integral roles in maintaining quality assurance and regulatory compliance. Practitioners must develop clear processes to differentiate the two effectively while ensuring robust documentation and validation practices are maintained throughout.

Risk-Based Change Thresholds in Pharma Validation

Implementing risk-based change thresholds is vital for streamlining change control processes. These thresholds help define when an established process necessitates re-validation or when verification suffices. This section will guide you through establishing these thresholds through a systematic approach.

To create risk-based change thresholds, follow these steps:

• Step 1: Categorize Changes – Classify changes into categories based on their potential impact on product quality, e.g., minor, moderate, and major changes.
• Step 2: Define Criteria for Each Category – Establish specific criteria for each change category, detailing the evidence required versus the level of change severity.
• Step 3: Use Historical Data – Analyze historical data from previous changes, effectiveness checks, and past re-validations to refine thresholds and criteria further.
• Step 4: Involve Cross-Functional Teams – Collaboration with cross-functional teams, including quality, manufacturing, and regulatory affairs, ensures a holistic view of risks associated with each category.
• Step 5: Document and Review – Document the established thresholds and continuously review them to adapt to new products, technologies, and processes.

Establishing clear thresholds minimizes unnecessary over-regulation of low-risk changes while ensuring that high-risk modifications are adequately assessed and validated in line with industry standards.

Bridging Studies: Making the Case for Change

Bridging studies play a critical role in justifying changes, especially when moving from one validated state to another. They provide data and evidence to support the changes being proposed under the change control process, serving as an influential tool for addressing regulatory scrutiny. Understanding the methodology and protocol for conducting successful bridging studies can accelerate the change control process.

To effectively conduct bridging studies, consider these essential steps:

• Step 1: Define Objectives – Clearly articulate the aim of the bridging study and the specific changes being evaluated. What do you aim to prove or clarify?
• Step 2: Develop a Study Design – Create a study design that utilizes prior knowledge and current production data, focusing on statistical methods to establish a correlation between the new and old configurations.
• Step 3: Collect Data – Gather relevant data points from historical processes, quality metrics, and any pilot runs conducted under the new conditions.
• Step 4: Analyze Results – Perform a comparative analysis between old and new processes, highlighting any significant deviations or impacts on CPV limits.
• Step 5: Prepare Documentation – Compile a comprehensive report outlining the findings and conclusions from the bridging study, supporting claims for the change proposed during the change control process.

Bridging studies not only validate the new approaches but also provide a security blanket against regulatory concerns, efficiently addressing potential issues before they arise.

Sampling Plan Updates and CPV Limit Adjustments

In pharmaceutical manufacturing, adjustments to sampling plans and CPM limit settings are often necessary following a change, either due to process evolution or environmental factors. Effectively managing these changes is essential for maintaining product quality and regulatory compliance.

When adjusting sampling plans and CPV limits, the following procedures should be followed:

• Step 1: Review Existing Data – Access historical data regarding quality performance metrics, including previous sampling plans, CPV limits, and their effectiveness in maintaining product quality.
• Step 2: Analyze Risks – Conduct a risk assessment considering potential impacts on the product caused by the proposed updates. Consider statistical methods to evaluate the appropriateness of the proposed sampling plan.
• Step 3: Modify Plans and Limits – Adjust the sampling plans and CPV limits based on analysis results and defined risk-based thresholds. Ensure the new limits align with regulatory expectations.
• Step 4: Gain Consensus – Collaborate with cross-functional teams to gather input and reach consensus on the updates before implementing changes.
• Step 5: Training and Documentation – Ensure all relevant personnel are trained on the updated sampling plans and limits while maintaining robust documentation for audits and future reviews.

The process of updating sampling plans and CPV limits ensures continuous improvement of quality systems, essential for meeting the expectations of regulatory bodies across the US, UK, and EU.

Implementing Effective Evidence Packs for Change Control

Evidence packs serve as a strong foundation for validation and change control efforts. They encapsulate all necessary documentation to support change claims, addressing regulatory inquiries and ensuring that change processes are justified.

To compile effective evidence packs, follow these steps:

• Step 1: Identify Required Documentation – Determine the necessary supporting documents, such as validation protocols, analytical results, bridging study conclusions, and previous impact assessments.
• Step 2: Organize Evidence Logically – Arrange documentation in a clear and systematic manner, grouping related materials and ensuring that they flow logically for reviewers.
• Step 3: Focus on Clarity and Completeness – Ensure clarity in your documentation, avoiding jargon where possible, and providing complete explanations of methodologies and results.
• Step 4: Maintain Version Control – Implement version control for all documents in the evidence pack to ensure that the most current versions are available during audits and assessments.
• Step 5: Review and Approve – Have evidence packs peer-reviewed internally by quality assurance and regulatory affairs professionals before submission or presentation.

By compiling effective evidence packs, organizations can support their case for changes confidently and enhance the transparency of their change control processes.

Effectiveness Checks and Periodic Review: Maintaining Quality

An essential part of quality assurance is ensuring that processes remain effective over time. Effectiveness checks and periodic reviews are the mechanisms businesses must utilize to maintain product quality and compliance following any implemented changes.

To perform thorough effectiveness checks and periodic reviews, adopt the following process:

• Step 1: Establish a Review Schedule – Create a schedule for periodic reviews that aligns with regulatory guidelines, such as those set forth in PIC/S expectations.
• Step 2: Collect Performance Data – Gather data from batches produced under the current process to evaluate performance consistency against predetermined quality metrics.
• Step 3: Analyze Findings – Employ statistical analysis to determine if performance meets predefined criteria and thresholds, and ensure ongoing CPV limit adherence.
• Step 4: Document Outcomes – Maintain detailed records of findings and any adjustive actions taken within the effectiveness checks or periodic reviews.
• Step 5: Review Results with Stakeholders – Regularly discuss outcomes and implications with relevant stakeholders to ensure alignment and foster a culture of continuous improvement in product quality.

Conducting consistent effectiveness checks and periodic reviews not only fulfills regulatory obligations but also strengthens an organization’s commitment to delivering high-quality pharmaceutical products.